Beta Drugs reports Q3 FY26 unaudited results, raises focus on higher-margin products and lowers FY26 revenue target to INR 400 crores; FY27 outlook grows to INR 530 crores with NDDS launches and expanded exports.
AI Assistant
Beta Drugs Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.